Abstract: A diagnostically useful carrier includes a means for specifically capturing an antibody to a polypeptide from the group including squid MLC1 or squid MLC2 or a variant thereof in a sample from a subject. A method includes the step detecting in a sample from a subject the presence or absence of an antibody to squid MLC1 or squid MLC2. The polypeptide or the carrier or a polypeptide binding specifically to an IgE antibody from the sample of a patient to squid MLC1 or squid MLC2 are useful for the manufacture of a diagnostic kit, preferably for the diagnosis of allergy.

Abstract: A diagnostically useful carrier includes a means for specifically capturing an antibody to a polypeptide from the group including squid MLC1 or squid MLC2 or a variant thereof in a sample from a subject. A method includes the step detecting in a sample from a subject the presence or absence of an antibody to squid MLC1 or squid MLC2. The polypeptide or the carrier or a polypeptide binding specifically to an IgE antibody from the sample of a patient to squid MLC1 or squid MLC2 are useful for the manufacture of a diagnostic kit, preferably for the diagnosis of allergy.

Abstract: A diagnostically useful carrier includes a means for specifically capturing an antibody to a polypeptide from the group including squid MLC1 or squid MLC2 or a variant thereof in a sample from a subject. A method includes the step detecting in a sample from a subject the presence or absence of an antibody to squid MLC1 or squid MLC2. The polypeptide or the carrier or a polypeptide binding specifically to an IgE antibody from the sample of a patient to squid MLC1 or squid MLC2 are useful for the manufacture of a diagnostic kit, preferably for the diagnosis of allergy.

Abstract: A diagnostically useful carrier has a polypeptide for specifically capturing an antibody to Ara h 7 isotype 7.0201 in a sample from a subject. A method includes detecting in a sample from a subject the presence or absence of an antibody to Ara h 7 isotype 7.0201. A pharmaceutical composition includes Ara h 7 isotype 7.0201 or a variant thereof.

Abstract: Provided is a polypeptide comprising a macadamia protein running in a 2D SDS PAGE at pH 6.3 to 8.7 and 53 to 67 kDa or a protein running in a 2D SDS PAGE at pH 6.5 to 7.9 and 20 to 25 kDa or an antigenic variant thereof, and a tag for detection and/or purification, a polypeptide fused with the macadamia protein, or the macadamia protein is modified by glycosylation, phosphorylation, acetylation, decarboxylation, citrullination, or hydroxylation.

Abstract: A diagnostically useful carrier has a polypeptide for specifically capturing an antibody to Ara h 7 isotype 7.0201 in a sample from a subject. A method includes detecting in a sample from a subject the presence or absence of an antibody to Ara h 7 isotype 7.0201. A pharmaceutical composition includes Ara h 7 isotype 7.0201 or a variant thereof.

Abstract: Provided is a polypeptide comprising a macadamia protein running in a 2D SDS PAGE at pH 6.3 to 8.7 and 53 to 67 kDa or a protein running in a 2D SDS PAGE at pH 6.5 to 7.9 and 20 to 25 kDa or an antigenic variant thereof, and a tag for detection and/or purification, a polypeptide fused with the macadamia protein, or the macadamia protein is modified by glycosylation, phosphorylation, acetylation, decarboxylation, citrullination, or hydroxylation.

Abstract: The present invention relates to a polypeptide comprising an antigenic fragment having a sequence of at least seven amino acids from a hydrophilic domain of an oil body-associated protein, wherein the polypeptide comprises a truncated hydrophobic domain of the oil body-associated protein or does not comprise such a domain, and wherein the oil body-associated protein is selected from the group comprising oleosin, caleosin and steroleosin, to a pharmaceutical composition or a vaccine comprising the polypeptide, to a complex comprising the polypeptide and an antibody bound thereto, to a medical or diagnostic device comprising the polypeptide, to a nucleic acid encoding the polypeptide or a cell comprising said nucleic acid, to a test kit comprising the polypeptide, and to a method for detecting an antibody which binds to the polypeptide.

Abstract: Compositions and methods are provided for decreasing blood glucose levels in an animal or for preventing or delaying the onset of a rise in blood glucose levels in an animal, comprising administering to the animal an antisense inhibitor of PTP1B expression in combination with at least one glucose-lowering drug. The present invention is also directed to compositions and methods for improving insulin sensitivity in an animal or for preventing or delaying the onset of insulin resistance in an animal. Also provided are compositions and methods for treating or preventing a metabolic condition in an animal. The metabolic condition may be, e.g., diabetes or obesity.

Abstract: The present invention relates to a method for producing a nucleosome preparation that is characterised by being suitable for use in immunofluorescence assays of specific antibodies directed against the nucleosomes in human samples and thus for a more specific diagnosis of disseminated lupus erythematosus (LED) compared with the state of the art.